The 3D Bioprinting Core at IUPUI and IU School of Medicine recently received two major boosts: Indiana CTSI core designation and funding from the National Institutes of Health (NIH) to cover the cost of its main bioprinting instrument.
The 3D Bioprinting Core also was awarded an NIH S10/Shared Instrument Grant to fund its Regenova bioprinter.
The core’s founding director, Nicanor Moldovan, PhD, an associate research professor with the School of Science at IUPUI and IU School of Medicine, said the 3D Bioprinting Core was created in 2016 when he attracted the Japanese company Cyfuse Biomedical to lend their advanced bioprinter to Indianapolis researchers for testing—making IUPUI the first academic institution in the world outside of Japan to benefit from this method of bioprinting.
The core uses a bioprinting method called “scaffold-free” because of its independence from the biomaterials, or “bio-inks,” traditionally used in bioprinting. Instead, the Regenova bioprinter robot skewers cellular spheroids into micro-needles to create living tissue-like constructs. True to its translational applications, the instrument is capable of creating tubular (vascular, tracheal, urethral), solid (bone, cartilage, heart muscle), or other cell-heterogeneous tissue constructs. These constructs can be used for in vitro drug or toxicological testing, or eventually for pre-clinical and clinical in vivo implantation.
The 3D Bioprinting Core’s users are trained to operate the instrument by themselves or they are assisted by the core manager Lester Smith, PhD.
Learn more at the 3D Bioprinting Core’s “Progress in Scaffold-Free Biofabrication” Symposium, presented by IUPUI and Johns Hopkins University, and second annual open house from 9 a.m. to 5 p.m. Friday, Sept. 15, in Walther Hall.